Skip to main content

Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.

Publication ,  Journal Article
Xian, Y; Xu, H; Lytle, B; Blevins, J; Peterson, ED; Hernandez, AF; Smith, EE; Saver, JL; Messé, SR; Paulsen, M; Suter, RE; Reeves, MJ ...
Published in: Circ Cardiovasc Qual Outcomes
January 2017

BACKGROUND: The implementation of Target: Stroke Phase I, the first stage of the American Heart Association's national quality improvement initiative to accelerate door-to-needle (DTN) times, was associated with an average 15-minute reduction in DTN times. TARGET: Stroke phase II was launched in April 2014 with a goal of promoting further reduction in treatment times for tissue-type plasminogen activator (tPA) administration. METHODS AND RESULTS: We conducted a second survey of Get With The Guidelines-Stroke hospitals regarding strategies used to reduce delays after Target: Stroke and quantify their association with DTN times. A total of 16 901 ischemic stroke patients were treated with intravenous tPA within 4.5 hours of symptom onset from 888 surveyed hospitals between June 2014 and April 2015. The patient-level median DTN time was 56 minutes (interquartile range, 42-75), with 59.3% of patients receiving intravenous tPA within 60 minutes and 30.4% within 45 minutes after hospital arrival. Most hospitals reported routinely using a majority of Target: Stroke key practice strategies, although direct transport of patients to computed tomographic/magenetic resonance imaging scanner, premix of tPA ahead of time, initiation of tPA in brain imaging suite, and prompt data feedback to emergency medical services providers were used less frequently. Overall, we identified 16 strategies associated with significant reductions in DTN times. Combined, a total of 20 minutes (95% confidence intervals 15-25 minutes) could be saved if all strategies were implemented. CONCLUSIONS: Get With The Guidelines-Stroke hospitals have initiated a majority of Target: Stroke-recommended strategies to reduce DTN times in acute ischemic stroke. Nevertheless, certain strategies were infrequently practiced and represent a potential immediate target for further improvements.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

January 2017

Volume

10

Issue

1

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Time-to-Treatment
  • Time Factors
  • Thrombolytic Therapy
  • Stroke
  • Quality Indicators, Health Care
  • Quality Improvement
  • Practice Guidelines as Topic
  • Infusions, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xian, Y., Xu, H., Lytle, B., Blevins, J., Peterson, E. D., Hernandez, A. F., … Fonarow, G. C. (2017). Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Circ Cardiovasc Qual Outcomes, 10(1). https://doi.org/10.1161/CIRCOUTCOMES.116.003227
Xian, Ying, Haolin Xu, Barbara Lytle, Jason Blevins, Eric D. Peterson, Adrian F. Hernandez, Eric E. Smith, et al. “Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.Circ Cardiovasc Qual Outcomes 10, no. 1 (January 2017). https://doi.org/10.1161/CIRCOUTCOMES.116.003227.
Xian Y, Xu H, Lytle B, Blevins J, Peterson ED, Hernandez AF, et al. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1).
Xian, Ying, et al. “Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.Circ Cardiovasc Qual Outcomes, vol. 10, no. 1, Jan. 2017. Pubmed, doi:10.1161/CIRCOUTCOMES.116.003227.
Xian Y, Xu H, Lytle B, Blevins J, Peterson ED, Hernandez AF, Smith EE, Saver JL, Messé SR, Paulsen M, Suter RE, Reeves MJ, Jauch EC, Schwamm LH, Fonarow GC. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1).

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

January 2017

Volume

10

Issue

1

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Time-to-Treatment
  • Time Factors
  • Thrombolytic Therapy
  • Stroke
  • Quality Indicators, Health Care
  • Quality Improvement
  • Practice Guidelines as Topic
  • Infusions, Intravenous